CCCC News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CC

Mkt Cap

$342.0M

Volume

2.18M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings.Zacks Investment Research · Oct 9, 2026

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingC4 Therapeutics presented biomarker data from its Phase 1 trial of cemsidomide combined with dexamethasone in relapsed/refractory multiple myeloma patients, demonstrating robust T-cell activation and immune cell function. The company also shared preliminary data from a Phase 1b trial combining cemsidomide with elranatamab, showing enhanced CD8+ T-cell expansion and prevention of T-cell exhaustion. The 75 µg dose level was declared safe, allowing advancement to dose escalation and expansion cohorts with full data expected in mid-2027.GlobeNewswire Inc. · Sep 25, 2026

C4 Therapeutics to Participate in Upcoming ConferencesC4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced its management will participate in three major healthcare conferences in May and June 2026, including TD Cowen's Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. The company is progressing targeted oncology programs and leveraging its TORPEDO platform for drug development.GlobeNewswire Inc. · May 20, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026C4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 in New York. The company is progressing targeted oncology programs including cemsidomide Phase 2 MOMENTUM trial expected to initiate in Q1 2026 and a Phase 1b combination trial with elranatamab planned for Q2 2026.GlobeNewswire Inc. · Feb 4, 2026

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysC4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall response rate at the highest dose. The company also outlined a new discovery strategy targeting inflammation and neurodegenerative diseases, with cash runway extending through end of 2028.GlobeNewswire Inc. · Jan 14, 2026

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceC4 Therapeutics, a clinical-stage biopharmaceutical company focused on protein degradation science, will participate in the 8th Annual Evercore Healthcare Conference on December 3rd, 2025, presenting a fireside chat with live webcast.GlobeNewswire Inc. · Nov 25, 2025

Why C4 Therapeutics Stock Crushed the Market on MondayC4 Therapeutics saw a significant stock price increase of over 34% after Stephens analyst Sudan Loganathan upgraded the stock to overweight, citing promising pipeline progress and potential in multiple myeloma drug market.The Motley Fool · Sep 15, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsC4 Therapeutics reported positive data for its multiple myeloma drug candidate cemsidomide, with a 50% overall response rate at the highest dose level. The company is prioritizing the development of cemsidomide and plans to seek partnership opportunities for its BRAF program.GlobeNewswire Inc. · May 7, 2025

BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsightThe BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.GlobeNewswire Inc. · Jan 29, 2025

NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ CountriesThe global NUT midline carcinoma treatment market is expected to grow from $21.88 billion in 2023 to $79.38 billion by 2034, driven by increased investment in cancer research, advances in targeted therapy, and growing awareness of rare cancers. North America and Asia Pacific are expected to be the key growth regions.GlobeNewswire Inc. · Jan 9, 2025

CC

CCCCC4 Therapeutics, Inc.

CCCC

Pay with—

Available Balance0.00

Your PositionYou don't own any CCCC yet.

Related Tickers

Earnings